Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1966 1
1970 1
1973 2
1976 1
1977 1
1982 3
1983 3
1985 2
1986 3
1987 3
1989 2
1990 2
1991 2
1993 1
1994 2
1995 6
1996 2
1997 4
1998 2
1999 4
2000 2
2001 3
2003 1
2004 4
2005 9
2006 5
2007 3
2008 5
2009 6
2010 7
2011 10
2012 10
2013 10
2014 18
2015 9
2016 5
2017 8
2018 5
2019 5
2020 15
2021 13
2022 16
2023 18
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: held g. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF. Jaramillo S, et al. Among authors: held g. Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45. Blood Cancer J. 2017. PMID: 28548643 Free PMC article. Clinical Trial.
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, Ueno H, Staiger AM, Ziepert M, Asmar F, Locher BN, Toth E, Weber T, Amini RM, Klapper W, Bouzani M, Poeschel V, Rosenwald A, Held G, Campo E, Ishaque N, Stamatopoulos K, Kanellis G, Anagnostopoulos I, Bullinger L, Goldschmidt N, Zinzani PL, Bödör C, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F. Noerenberg D, et al. Among authors: held g. J Clin Oncol. 2024 Feb 1;42(4):452-466. doi: 10.1200/JCO.23.01053. Epub 2023 Dec 6. J Clin Oncol. 2024. PMID: 38055913
Postmastectomy lymphedema.
Held GR. Held GR. CA Cancer J Clin. 1982 Jan-Feb;32(1):63. doi: 10.3322/canjclin.32.1.63-a. CA Cancer J Clin. 1982. PMID: 6799167 Free article. No abstract available.
Buried interfaces: general discussion.
Aureau D, Bartels-Rausch T, Buckingham MA, Conard T, Dell'Angela M, Flavell W, Gibson JS, Held G, Isaacs M, Kastorp CFP, Krizan A, Lindsay R, Lömker P, Morgan D, Osundare A, Palgrave R, Pei Y, Renault O, Roberts A, Rupprechter G, Shard A, Solal F, Spencer B, Weatherup R. Aureau D, et al. Among authors: held g. Faraday Discuss. 2022 Aug 25;236(0):338-351. doi: 10.1039/d2fd90026b. Faraday Discuss. 2022. PMID: 35920282 No abstract available.
B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma.
Thurner L, Fadle N, Regitz E, Roth S, Cetin O, Kos IA, Hess SM, Bein J, Bohle RM, Vornanen M, Sundström C, De Leval L, Tiacci E, Borchmann P, Engert A, Poeschel V, Held G, Schwarz EC, Neumann F, Preuss KD, Hoth M, Küppers R, Lehman K, Hansmann ML, Becker SL, Bewarder M, Hartmann S. Thurner L, et al. Among authors: held g. Haematologica. 2023 Dec 1;108(12):3347-3358. doi: 10.3324/haematol.2023.282698. Haematologica. 2023. PMID: 37139600 Free PMC article.
Management of diffuse large B-cell lymphoma (DLBCL).
Kubuschok B, Held G, Pfreundschuh M. Kubuschok B, et al. Among authors: held g. Cancer Treat Res. 2015;165:271-88. doi: 10.1007/978-3-319-13150-4_11. Cancer Treat Res. 2015. PMID: 25655614 Review.
Lessons of Studying TRP Channels with Antibodies.
Meissner M, Obmann VC, Hoschke M, Link S, Jung M, Held G, Philipp SE, Zimmermann R, Flockerzi V. Meissner M, et al. Among authors: held g. In: Zhu MX, editor. TRP Channels. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 6. In: Zhu MX, editor. TRP Channels. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 6. PMID: 22593962 Free Books & Documents. Review.
215 results